Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. A. Medvedeva has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of a prospective, observational, multicenter study of patients with hypertension and chronic kidney disease in the Russian Federation (PRIORITY-CKD)

    by E. V. Shlyakhto, G. P. Arutyunov, M. M. Batyushin, S. V. Villevalde, N. E. Zvartau, S. V. Nedogoda, E. M. Shilov, A. E. Soloveva, E. A. Medvedeva, E. A. Zorina, et al.

    Aim. To assess the incidence of chronic kidney disease (CKD) in adult patients with hypertension (HTN) and markers of CKD without concomitant diabetes and symptomatic heart failure, as well as to describe the clinical and demographic characte­ristics and treatment options in the overall cohort and a subgroup with verified CKD. Material and methods. PRIORITY-CKD is a multicenter, observational, prospective study with a retrospective analysis of patients with hypertension and markers of CKD in the Russian Federation. The study design has been described in detail previously. Results. The analytical cohort included 9914 patients. The diagnosis of CKD was confirmed in 8430 (85%) patients with HTN and CKD markers during the study as follows: 3795 (38,3%) at Visit 1 and 4635 (46,8%) at Visit 2. The estimated glomerular filtration rate was used as diagnostic criteria in 8406 (97,4%) cases. Albuminuria/proteinuria and a combination of markers were used in 13 (0,2%) and 11 (0,1%) patients, respectively. In the overall cohort and the subgroup with verified CKD, women predominated, the median duration of hypertension was similar and amounted to 10 years. More than half of the patients had stage III hypertension and the very high cardiovascular risk ca­tegory. A high frequency of metabolic risk factors (overweight, abdominal obesity, dyslipidemia) and coronary artery disease (33%/34,9% in the two cohorts, respectively) was observed. Uncontrolled blood pressure (BP) (systolic BP ≥140 and/or diastolic BP ≥90 mm Hg while receiving antihypertensive therapy (AHT)) and signs of AHT resistance were detected in 36,0% and 6,0% of patients in the overall cohort, respectively, and in the same proportion of patients in the CKD subgroup. Combination AHT was received by 72,3% of patients in the study cohort after Visit 1. After CKD diagnosis was confirmed, sodium-glucose cotransporter type 2 inhibitors were prescribed in 31,1% of cases. Conclusion. In the Russian population, CKD was confirmed in 85% of patients with HTN and CKD markers. Albuminuria/proteinuria was assessed extremely rarely. A high frequency of uncontrolled HTN, a significant burden of metabolic risk factors, and cardiovascular disease were observed in the overall cohort and the CKD subgroup. The incremental use of renoprotective therapy after verification of the CKD diagnosis was insufficient.

  • Open Access

    Evolution of the concept of metabolic syndrome and its place in the International Classification of Diseases

    by E. V. Shlyakhto, S. V. Nedogoda, N. E. Zvartau, S. V. Villevalde, E. A. Medvedeva, E. I. Usova, Е. В. Шляхто, С. В. Недогода, Н. Э. Звартау, С. В. Виллевальде, et al.

    The evolving understanding of metabolic syndrome (MS) as a multiorgan clinical and pathophysiological continuum conflicts with the prevailing principles of its statistical evaluation, which are based primarily on the isolated coding of indivi­dual components. This article analyzes the transformation of approaches to meta­bolic syndrome coding in various versions of the International Classification of Diseases and rela­ted health problems from the perspective of modern concepts of cardiovascular-renal-metabolic and cardiovascular-renal-hepatic-metabolic syndromes. The presented prospects for the implementation of independent coding of metabolic syndrome reflect not a change in nosological status, but rather the natural evolution of classification systems in the context of the development of patient-centered healthcare models.

  • Open Access

    Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee

    by E. V. Shlyakhto, G. P. Arutyunov, A. Yu. Babenko, S. A. Boytsov, S. V. Villevalde, I. I. Dedov, O. M. Drapkina, S. O. Eliashevich, N. E. Zvartau, V. T. Ivashkin, et al.

    Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee | Shlyakhto | Russian Journal of Cardiology Согласительные междисциплинарные позиции наблюдательного комитета по метаболическому синдрому | Шляхто | Российский кардиологический журнал


  • Open Access

    Metabolic Syndrome: A Registry Study of Patients in the Russian Federation (METEOR). Rationale, objectives, design, and methodology

    by E. V. Shlyakhto, N. E. Zvartau, S. V. Villevalde, S. V. Nedogoda, E. A. Medvedeva, E. I. Usova, V. A. Karlina, M. V. Dubinina, Е. В. Шляхто, Н. Э. Звартау, et al.

    This paper presents the rationale, design, and methodology of the prospective, observational, multicenter study "Metabolic Syndrome: A Registry Study of Patients in the Russian Federation (METEOR)". The are following study aims: to describe the clinical and demographic characteristics, diagnostic methods, and treatment options used in outpatients with metabolic syndrome (MS) in a real-world clinical practice; to evaluate baseline characteristics and progression across MS stages within various phenotypes; and to identify factors associated with clinical outcomes during the follow-up period in the general patient population and in subgroups of interest. The study will sequentially enroll all adult outpatients with MS who are followed up by a general practitioner, primary care physician, and/or specialized professionals, who have signed an informed consent, and who meet the inclusion criteria. Data will be collected on a single digital platform in the patient’s electronic individual case report form. The follow-up period begins on the day of Visit 1, with Visit 2 occurring 6 months (±3 months) after Visit 1. Visit 3 and subsequent visits will be conducted 12 months (±3 months) after Visit 1, and then annually thereafter collect information on the patient’s clinical status and endpoints.

  • Open Access

    Prevalence, clinical, and prognostic role of metabolic syndrome in patients with heart failure: A subanalysis of the PRIORITY-HF study

    by E. V. Shlyakhto, Yu. N. Belenkov, S. A. Boytsov, S. V. Villevalde, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, V. Yu. Mareev, et al.

    Aim. To assess the prevalence of individual components of metabolic syndrome (MS), the incidence of MS, and its clinical and prognostic significance in outpatients with heart failure (HF). Material and methods. This retrospective analysis of data from the PRIORITY-HF multicenter registry study of patients with HF in the Russian Federation was conducted. The analytical cohort included 19939 patients, and the primary and se­condary criteria of MS were analyzed. A group with MS was identified according to diagnostic criteria, and combinations of components were assessed. In addition, cluster analysis was performed, and prognosis was evaluated. Results. In the analyzed cohort, the primary criteria of MS were identified with high frequency as follows: obesity in 45,6%, HTN in 89%, and type 2 diabetes in 27,4% of patients. Among the additional criteria, the highest prevalence was observed for dyslipidemia/lipid-lowering therapy in 80,7%, impaired renal function/damage in 62%, and hyperuricemia/urate-lowering therapy in only 5% of patients. MS was diagnosed in 14403 (70,4%) patients. Among patients with MS, the following distribution was noted depending on the burden of main criteria: 48,8% — 2, 28% — 1, and 23,2% — 3 main criteria. The most frequent combination was HTN + dyslipidemia/lipid-lowering therapy + impaired renal function/damage both in the overall cohort with MS and in the subgroups by left ventricular ejection fraction. Patients with HF with preserved ejection fraction, compared with other phenotypes, had a higher frequency of combinations with 3 main criteria in the composition. Patients with metabolic syndrome (MS) had a significantly higher risk of hospita­lization for cardiovascular causes (odds ratio 1,142, 95% confidence interval 1,033-1,263) than patients without MS (p=0,01). Among the identified MS clusters, cluster 1 was characterized by older patient age, a greater burden of kidney impairment/da­mage, and the poorest prognosis. Conclusion. A high prevalence of individual MS components was found among patients with heart failure. MS was diagnosed in 70,4% of cases. The broad profile of the obtained combinations of MS components reflects the diversity of me­tabolic disorders in HF patients. MS was associated with a significantly increased risk of hospitalization for cardiovascular causes compared to patients without MS. Cluster analysis demonstrated heterogeneity of patients with MS in clinical cha­racteristics and prognosis.

  • The use of direct oral anticoagulants: Focus on dosing schedule and net clinical benefit

    by E. A. Medvedeva, S. V. Villevalde

    Evaluation of the net clinical benefit of anticoagulant therapy is an important tool that helps compare thromboembolic and hemorrhagic risks. The net clinical benefit of direct oral anticoagulants (DOACs) exceeds that of warfarin and demonstrates their significant advantage in various patient categories. The dosing schedule of DOACs (once or twice daily) influences peak plasma drug concentrations and continuity of their action, which is particularly important if a patient misses or takes an extra dose incidentally. Twice daily dosing of DOACs may be safer due to less variability in drug concentrations and, according to some data, has a more favorable net clinical benefit profile determined by both thrombotic and hemorrhagic risks. Different DOACs have their own pharmacokinetic properties and interand intra-individual variability in plasma concentrations. It should be considered that the degree of factor Xa inhibition is not only influenced by the administration schedule, dosage, and characteristics of the drug, but also by the phenotypic characteristics of the patients. Further studies exploring the personalized approach to anticoagulant therapy appear promising. Patient adherence to DOACs is determined by multiple factors and, according to current data, varies between medications for once-daily (QD) vs. twice-daily (BID) dosing, which suggests more of a role of the molecule itself and its associated tolerability and side effects. Apixaban has demonstrated the greatest clinical benefit for patients with atrial fibrillation, both in randomized controlled trials and in real-world clinical practice, due to the greatest reduction in the risk of major hemorrhagic complications.

  • Open Access

    Evaluation, clinical and prognostic role of chronic kidney disease markers in outpatients with heart failure in real-world practice: data from the PRIORITY-HF study

    by E. V. Shlyakhto, Yu. N. Belenkov, S. A. Boytsov, С. В. Виллевальде, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, V. Yu. Mareev, et al.

    Aim. To evaluate markers of chronic kidney disease (CKD) and their clinical and prognostic role in outpatients with heart failure (HF) based on real-world data.Material and methods. This retrospective analysis of data from the prospective observational multicenter registry study of patients with heart failure in Russia (PRIORITY-HF) was performed, including 19981 patients. To assess CKD markers, the following data obtained at Visit 1 were taken into account: "Has the diagnosis of Chronic Kidney Disease (CKD) been confirmed?", "CKD stage", "CKD-EPI Estimated glomerular filtration rate (eGFR)", "Creatinine", "Albumin" or "Albumin/ creatinine ratio" in a single urine portion. eGFR values entered in case report form were compared with the CKD-EPI 2021 eGFR values based on the patient’s sex, age and the entered serum creatinine (aGFR). Clinical characteristics, therapy after Visit 1 and prognosis were compared in patients with CKD and depending on aGFR value.Results. The following diagnostic problems were identified: incorrect GFR estimation with more frequent underestimation of values and insufficient assessment of albuminuria. CKD was noted as a concomitant diagnosis in 44,7% of patients with HF, but aGFR 2 was determined in 30,8% of cases. Groups with both reported CKD and aGFR were characterized by a more severe HF course, a greater burden of most cardiovascular and non-cardiovascular (obesity, diabetes mellitus and anemia) comorbidities. A decrease in prescription rate of most classes of guideline-directed medical therapy for HF and quadruple therapy with aGFR 2 was noted. Both CKD and a decrease in aGFR 2 were associated with a higher rate of adverse events. A decrease in eGFR by every 10 ml/min/1,73 m2 was significantly associated with all adverse outcomes with extensive adjustment.Conclusion. The high prevalence of CKD in the cohort of HF patients, the identified diagnostic problems, a more severe clinical course of HF, and an unfavorable prognosis emphasize the need for comprehensive measures to increase physician awareness and optimize the implementation of guidelines in real-world practice.


  • Open Access

    Resistance and control of hypertension in patients with heart failure according to the PRIORITY-HF study

    by E. V. Shlyakhto, Yu. N. Belenkov, S. A. Boytsov, С. В. Виллевальде, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, V. Yu. Mareev, et al.

    Aim. To assess the frequency, associated factors, features of hypertension (HTN) treatment and prognosis depending on blood pressure (BP) control and resistance to antihypertensive therapy (AHT) in outpatients with heart failure (HF).Material and methods. This retrospective analysis of data from 19938 PRIORITYHF study participants with BP data at Visit 1 was performed. No BP control was defined as systolic and/or diastolic BP ≥140 and/or 90 mm Hg. In the absence of BP control on triple AHT (renin-angiotensin-aldosterone system inhibitor + calcium channel blocker + thiazide/thiazide-like diuretic) or BP control while taking triple AHT in combination with at least one other antihypertensive class, resistant HTN (uncontrolled and controlled, respectively) was diagnosed.Results. HTN was diagnosed in 17750 (89,0%) patients, of which 32,1% were uncontrolled and 10,2% were resistant (including 4,5% as uncontrolled). In multivariate logistic regression, obesity, type 2 diabetes, and more severe congestion increased the probability of uncontrolled resistant HTN. Initiation of at least one new class of antihypertensives was noted in 2005 (35,2%) patients with uncontrolled HTN and in 152 (19%) patients with uncontrolled resistant HTN. Loop diuretics, mineralocorticoid receptor antagonists, and beta-blockers were most often added to therapy. Underuse of quadruple therapy was noted in HF with reduced ejection fraction, especially in uncontrolled HTN. In the overall group, the death risk was lower in uncontrolled HTN — odds ratio (OR) 0,798 [95% confidence interval (CI) 0,6810,935]. An independent association was found between uncontrolled resistant HTN and an increased probability of all-cause (OR 1,406 [95% CI 1,223-1,615], cardiovascular (OR 1,4 [95% CI 1,172-1,673]) and HF-related (OR 1,475 [95% CI 1,088-2]) hospitalizations with no significant differences between subgroups in ejection fraction (p for correlation >0,05).Conclusion. No BP control was detected in every third patient with HF and HTN. The association of uncontrolled resistant HTN with metabolic comorbidities, risk of hospitalization, and the need for multicomponent therapy require increased awareness among physicians about the tactics of managing patients with a combination of different phenotypes of HF and HTN.


  • Open Access

    Prevalence, clinical and prognostic role of type 2 diabetes in patients with heart failure: a subanalysis of the PRIORITY-HF study

    by E. V. Shlyakhto, Yu. N. Belenkov, S. A. Boytsov, С. В. Виллевальде, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, V. Yu. Mareev, et al.

    Aim. To assess the prevalence, clinical features and prognostic value of type 2 diabetes (T2D) in outpatients with heart failure (HF).Material and methods. According to the PRIORITY-HF study, a retrospective analysis of T2D prevalence, features of control and treatment of related comorbid conditions was performed in a cohort of 19939 patients with HF. The prognostic role of T2D and glycatedhemoglobin (HbA1c) was estimated using the multivariate Cox regression model. Results. The prevalence of T2D in patients with HF was 27,4%. The HbA1c level at visit 1 was determined in 37,6% of patients with T2D and in 11,6% of cases without T2D. Patients with T2D compared to those without T2D were characterized by a higher burden of cardiovascular comorbidities and such non-cardiac concomitant conditions as chronic kidney disease, anemia, bronchial asthma. Patients with T2D had a higher functional class, longer duration of HF, and a greater HF-related hospitalization rate. At baseline, T2D was associated with more frequent prescription of angiotensin II receptor blockers, renin-angiotensin-aldosterone system blockers, mineralocorticoid receptor antagonists, beta-blockers, sodium-glucose cotransporter-2 (SGLT2) inhibitors. After visit 1, both subgroups showed a prescription rate increase in all classes of guideline-directed medical therapy (GDMT), especially SGLT2 inhibitors. The proportions of patients receiving target GDMT doses were low in both subgroups with and without T2D, but titration of doses of all GDMT classes was more effective among patients with T2D. Metformin was most often used for glycemic control, followed by SGLT2 inhibitors and sulfonylureas, which are not front-line therapy for HF. Patients with T2D were characterized by a more unfavorable prognosis compared to the cohort without T2D. In the subgroup of patients with T2D, HbA1c >9% was associated with an increased all-cause mortality, as well as all-cause and HF-related hospitalization rates.Conclusion. T2D in patients with HF is associated with a more severe HF course, worsens the prognosis and requires increased awareness of physicians on the diagnostic and therapeutic tactics for managing this cohort of patients.


  • Open Access

    Prevalence, clinical and prognostic significance of chronic obstructive pulmonary disease in outpatients with heart failure: a subanalysis of the prospective multicenter registry study PRIORITY-HF

    by E. V. Shlyakhto, S. N. Avdeev, Yu. N. Belenkov, S. A. Boytsov, С. В. Виллевальде, A. S. Galyavich, M. G. Glezer, N. E. Zvartau, Zh. D. Kobalava, Yu. M. Lopatin, et al.

    Aim. To assess the prevalence, clinical features and prognosis of heart failure (HF) combined with chronic obstructive pulmonary disease (COPD) according to the prospective observational multicenter registry study of Russian patients with HF — PRIORITY-HF.Material and methods. The study included 19981 patients from 136 centers. Case report form was used to collect and analyze primary data. During the follow-up period, additional visits to the study centers were conducted at 6 and 12 months. Results. Overall prevalence of COPD in the examined cohort was 6,2%, while with HF with reduced (HFrEF), mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF) it was 7,5%/5,7%/5,4%, respectively (pConclusion. A low incidence of COPD was found in the outpatient cohort of patients with HF, which may be associated with underdiagnosis in real-world practice. Patients with a combination of HF and COPD had a more severe course of HF, more often used the main classes of guideline-directed medical therapy and quadruple therapy, and a higher risk of all-cause mortality and hospitalizations during 12-month follow-up.